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Abstract
Background: Women with a personal history of breast cancer are at increased risk of future breast cancer events, and
may benefit from supplemental screening methods that could enhance early detection of subclinical disease. However,
current literature on breast magnetic resonance (MR) imaging surveillance is limited. We investigated outcomes of
surveillance breast magnetic resonance (MR) imaging in women with a personal history of breast cancer.
Methods: We reviewed 1053 consecutive breast MR examinations that were performed for surveillance in 1044
women (median age, 53 years; range, 20–85 years) previously treated for breast cancer between August 2014 and
February 2016. All patients had previously received supplemental surveillance with ultrasound. Cancer detection rate
(CDR), abnormal interpretation rate and characteristics of MR-detected cancers were assessed, including extramammary
cancers. We also calculated the PPV1, PPV3, sensitivity and specificity for MR-detected intramammary lesions.
Performance statistics were stratified by interval following initial surgery.
Results: The CDR for MR-detected cancers was 6.7 per 1000 examinations (7 of 1053) and was 3.8 per 1000
examinations (4 of 1053) for intramammary cancers. The overall abnormal interpretation rate was 8.0%, and the
abnormal interpretation rate for intramammary lesions was 7.2%. The PPV1, PPV3, sensitivity and specificity for
intramammary lesions was 5.3% (4 of 76), 15.8% (3 of 19), 75.0% (3 of 4) and 98.3% (1031 of 1049), respectively. For MR
examinations performed ≤36 months after surgery, the overall CDR was 1.4 per 1000 examinations. For MR
examinations performed > 36 months after surgery, the overall CDR was 17.4 per 1000 examinations.
Conclusions: Surveillance breast MR imaging may be considered in women with a history of breast cancer,
considering the low abnormal interpretation rate and its high specificity. However, the cancer detection rate was low
and implementation may be more effective after more than 3 years after surgery.
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Background
Although women previously treated for breast cancer are
at a statistically significant increased risk of future breast
cancer events [1, 2], annual mammographic screening is
currently the only post-treatment imaging modality rec-
ommended for breast cancer follow-up by the American
Society for Clinical Oncology (ASCO) and the National
Comprehensive Cancer Network (NCCN) [3, 4].
There has been limited information on breast mag-
netic resonance (MR) imaging surveillance in this spe-
cific patient population. Previous screening trials using
MR imaging have focused on high-risk women without a
personal history of breast cancer, resulting in increased
invasive breast cancer yields at acceptable recall rates
and positive predictive values (PPV) of biopsy [5–8].
Surveillance breast MR imaging may also have potential
benefits in women previously treated for breast cancer,
primarily by overcoming the decreased sensitivity of
mammography in breasts with dense tissue and
treatment-related changes [9–11]. Despite advances in
locoregional and systemic therapy, recurrence or second
breast cancer rates are approximately 3% to 5% per year
even in early-stage hormone receptor-positive patients
[2, 12]. Therefore, this patient group would benefit from
supplemental screening methods that could enhance early
detection of subclinical disease and ultimately improve
relative survival [13, 14]. Previous studies have reported
that breast MR imaging depicted additional cancers even
after prior or concurrent negative findings of mammog-
raphy and ultrasound (US) [11, 15, 16]. However, due to
sparse data on surveillance breast MR imaging, the appro-
priate interval following surgery for initiation of MRI sur-
veillance has not yet been investigated.
At our institution, surveillance breast MR imaging has
recently been implemented as part of the routine post-
treatment surveillance protocol for patients previously
treated for breast cancer. These patients had previously
undergone routine supplemental surveillance with US.
As a result, we were able to obtain data from a large
group of patients regarding its performance stratified by
interval between definitive surgery and implementation
of MRI surveillance. The purpose of this study was to in-
vestigate the outcomes of surveillance breast MR im-
aging in women with a personal history of breast cancer.
Methods
Study population
This retrospective study was approved by the institu-
tional review board of Yonsei University College of
Medicine and the requirement for informed consent was
waived. Between August 2014 and February 2016, 1285
breast MR examinations were performed in 1266 women
who had been previously treated for breast cancer, either
with breast conserving surgery (BCS) (n = 648) or
mastectomy (n = 396). Among them, 222 women were
excluded either because they underwent MR imaging for
reasons other than postoperative surveillance (n = 70);
they had BRCA genetic mutations (n = 20); they had
undergone screening breast MR imaging prior to the
study period (n = 4); or their 12-month imaging follow-
up information was unavailable (n = 128) (Fig. 1). Finally,
1053 breast MR examinations that were performed for
surveillance in 1044 women (median age, 53 years; range,
20–85 years) with a personal history of breast cancer com-
posed our study population. Among them, 9 women
underwent two rounds of screening MR examinations
during the study period. Analysis of Breast Imaging
Reporting and Data System (BI-RADS) category assess-
ments of mammograms and US performed prior to MR
examinations revealed BI-RADS category 1 in 373 exami-
nations (35.4%), category 2 in 434 examinations (41.2%),
and category 3 in 246 examinations (23.4%). The median
follow-up period after surveillance breast MR imaging was
18.7 months (range, 12.0–30.7 months).
Post-treatment surveillance
After definitive breast cancer surgery, patients underwent
follow-up by clinical examination and breast US every
6 months and with mammography, chest radiography, ab-
dominal US and whole body bone scan every 12 months.
After 5 years following initial surgery, patients underwent
annual follow-up by breast US and mammography. Breast
MR imaging was implemented as part of the routine post-
treatment surveillance protocol in 2013, and thereafter pa-
tients underwent screening breast MR imaging instead of
US at approximately two and five years after surgery. Sur-
veillance breast MR imaging was also performed at the re-
quest of clinicians or patients.
The median interval between prior surveillance US
and MR examinations was 6.1 months (range, 0–
13.9 months). In 19 cases (1.8%), surveillance US and
MR imaging were performed on the same day at the
Fig. 1 Flowchart of study population selection
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request of the referring physician. The median interval
between prior mammography and MR examinations
was 11.5 months (range, 0–65.1 months).
MR imaging technique
Breast MR examinations were performed using two 3 −
Tesla MR scanners (Discover 750, GE Medical Systems,
Milwaukee, WI, USA; Ingenia, Philips Medical Systems,
Best, The Netherlands). Imaging was performed with a
dedicated phased array breast coil (8-channel GE or 16-
channel Philips) with the patient in the prone position.
Imaging was performed prior to a rapid bolus injection
of contrast agent and six times after injection. Sequences
included a three-plane localizing sequence, axial T2-
weighted fast-spin-echo and T2-stimulated inversion
recovery (STIR) sequence, and axial T1-weighted non-
fat-suppressed or fat-suppressed sequence before con-
trast administration. The bolus injection consisted of
0.2 mmol/kg body weight of gadolinium-based contrast
agent (Dotarem, Guerbet, Paris, France; Magnevist,
Berlex Laboratories, Wayne, NJ, USA; or Gadovist, Bayer
Scherming Pharma, AG, Berlin, Germancy) and a 20-mL
saline flush delivered at a rate of 2 ml/s. 3D dynamic
post-contrast enhanced (DCE) axial images are then per-
formed in the axial plane and a T1-weighted 3D delayed
postcontrast sequence is acquired in the sagittal plane.
Bilateral examinations were performed for all patients.
MR imaging evaluation
MR images were prospectively interpreted by one of four
radiologists with 6–15 years of experience in breast MR
imaging interpretation. Computer aided evaluation soft-
ware (CADstream, Confirma, Kirkland, WA) was used
for characterization of lesion kinetics. Of the 1044
women, 89.1% (930 of 1044) previously underwent pre-
operative MR imaging. Each MR examination was given
a Breast Imaging Reporting and Data System (BI-RADS)
final assessment category based on the breast lesion
morphology and kinetics.
We retrospectively reviewed MR imaging reports,
clinical and imaging records. For lesions assessed as
BI-RADS 3, follow-up breast MRI or US at 6–
12 months was recommended based on the presence
of a US-correlate on previous imaging and the period
of stability. BI-RADS category 3 was also given to
newly found lesions if its findings were probably be-
nign according to the BI-RADS MR lexicon [17]. For
breast or chest wall lesions that were assessed as BI-
RADS category 4 or 5, targeted US was first performed
and US-guided biopsy or MR-guided biopsy was per-
formed accordingly. For suspicious extramammary
findings found on breast MR imaging, further evalu-
ation with other imaging modalities was performed
with subsequent biopsy when needed.
Statistical analysis
Intramammary cancer was defined as cancer in the ipsilat-
eral breast following BCS or cancer in the contralateral
breast. Extramammary cancer was defined as locoregional
disease (cancer in the ipsilateral axilla, internal mammary
or supraclavicular lymph nodes or in the mastectomy bed)
and distant metastasis.
We calculated the overall cancer detection rate and
abnormal interpretation rates. The overall cancer detec-
tion rate for MRI was defined as the total number of
intramammary and extramammary cancers detected at
MR imaging per 1000 examinations. The overall abnor-
mal interpretation rate for MRI was defined as the per-
centage of MR examinations that were given BI-RADS
categories 0, 3, 4, 5 or those with findings suspicious for
extramammary cancer detected at MR imaging. Accord-
ing to the outcome monitoring section of the BI-RADS
5th edition atlas, we included BI-RADS category 3 in the
numerator of the abnormal interpretation rate because
further imaging is recommended before the next routine
screening [18].
We also calculated outcome measures for MR-
detected intramammary lesions. The cancer detection
rate for intramammary lesions was defined as the total
number of intramammary cancers detected at MR im-
aging per 1000 examinations. The abnormal interpret-
ation rate for intramammary lesions was defined as the
percentage of MR examinations that were given BI-
RADS categories 0, 3, 4, or 5. Positive MR examinations
were defined as those given BI-RADS categories 4 or 5.
Negative MR examinations were defined as those
assessed as BI-RADS categories 1, 2 or 3. MR examina-
tions with an initial BI-RADS category 0 assessment
were reclassified according to their final assessment.
PPV1 was defined as the percentage of MR examinations
with BI-RADS categories 0, 3, 4, 5 that resulted in a tis-
sue diagnosis of cancer. PPV3 was defined as the per-
centage of all known breast biopsies performed as a
result of positive MR examinations that resulted in a tis-
sue diagnosis of cancer. A true-positive (TP) result was
defined as a positive MR examination resulting in a diag-
nosis of cancer within 1 year. A true-negative (TN) re-
sult was defined as a negative MR examination and no
detection of cancer within 1 year. A false-negative (FN)
result was defined as a negative MR examination with a
diagnosis of cancer within 1 year. A false-positive (FP)
result was defined as a positive MR examination with no
detection of cancer within 1 year.
In addition, we stratified the above performance statis-
tics according to the interval between initial surgery and
surveillance MR imaging: (1) for MR examinations per-
formed at or less than a 36-month interval and (2) for
examinations performed at more than a 36-month inter-
val following initial surgery. Performance statistics were
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compared between the two groups using the Fisher exact
test. We also compared the intervals between prior sur-
veillance US and MR examinations by using the Student t
test. Statistical analyses were performed by using statistical
software (SPSS version 23.0; IBM Corp, Armonk, NY.).
Results
Table 1 shows the clinical-pathologic characteristics of the
1044 women who underwent screening breast MR exami-
nations. The median interval between initial surgery for
breast cancer and first-time screening MR examination
was 27.8 months (range, 12.1–167.3 months). The final as-
sessment categories of the 1053 examinations were as fol-
lows: BI-RADS category 1 in 545 examinations (51.8%),
BI-RADS category 2 in 432 examinations (41.0%), BI-
RADS category 3 in 54 (5.1%), BI-RADS category 4 in 21
examinations (2.0%), BI-RADS category 0 in 1 examin-
ation (0.1%). Three examinations assigned as BI-RADS
category 2 and five examinations assigned as BI-RADS
category 1 showed extramammary findings suspicious for
malignancy (0.8%, 8 of 1053).
Cancer detection yield for MRI
The overall abnormal interpretation rate for MRI was
8.0% (84 of 1053) and biopsy or further imaging was rec-
ommended for 29 examinations (2.7%) with 21 of the 29
exams classified as BI-RADS category 4 and the other 8
exams demonstrating extramammary lesions suspicious
for malignancy (Table 2). Of the 21 BI-RADS category 4
lesions, 18 lesions underwent image-guided biopsy (US-
guided biopsy [n = 16] or MR-guided biopsy [n = 2]) and
one lesion underwent surgical excision for a US correl-
ate. Among them, 3 lesions were diagnosed as cancer.
All three detected cancers were newly developed contra-
lateral breast cancer, with one cancer detected at a
second-round MR examination. Of the 54 lesions that
were BI-RADS category 3, one cancer was diagnosed
(1.8%). This lesion was an 8-mm enhancing mass at the
contralateral breast and moderate background parenchy-
mal enhancement on preoperative MR imaging per-
formed 5 years ago made accurate comparison difficult.
Because it was considered to have slightly increased in
size, ultrasound correlation was recommended and the
final assessment was upgraded to BI-RADS category 4 at
US. Subsequent US-guided biopsy yielded invasive
ductal carcinoma (Table 3). All of the four MR-detected
intramammary cancers were not detected on prior sur-
veillance US which was performed at a median interval
of 5.5 months (range, 4.6–12.4 months).
Among the 8 examinations with suspicious extramam-
mary findings, five were finally considered negative
based on image-guided biopsy (n = 3) or further imaging
evaluation (PET-CT, whole body bone scan) (n = 2) with
no evidence of malignancy for more than 1 year. Of the
three examinations with extramammary cancer, two were
histologically confirmed by US-guided biopsy (n = 1, chest
wall) or surgical excision (n = 1, mediastinal LN). The
remaining one patient was diagnosed with sternum metas-
tasis based on imaging alone, which was initially detected
on breast MRI and subsequently confirmed by whole body
bone scan and PET-CT (Table 4). Therefore, the overall
cancer detection rate for MRI was 6.7 per 1000 examina-
tions (7 of 1053).
Table 1 Characteristics of 1044 women with a personal history
of breast cancer
Characteristic
Age (years)a 53 (20–85)
Interval between initial surgery
and screening MRIa (months)
27.8 (12.1–167.3)
Preoperative breast MRI
Yes 930 (89.1%)
No 114 (10.9%)
Pathology of initial breast cancer
Ductal carcinoma in situ 185 (17.7%)
Invasive ductal carcinoma 729 (69.8%)
Invasive lobular carcinoma 33 (3.2%)
Tubular carcinoma 25 (2.4%)
Cribiform carcinoma 3 (0.3%)
Mucinous carcinoma 23 (2.2%)
Invasive micropapillary carcinoma 6 (0.6%)
Metaplastic carcinoma 6 (0.6%)
Solid papillary carcinoma 10 (1.0%)
Others 24 (2.3%)
Type of surgery
Partial mastectomy 648 (62.1%)
Mastectomy 396 (37.9%)
Pathological T stage
TX 15 (1.4%)
T0 27 (2.6%)
Tis 188 (18.0%)
T1 624 (59.8%)
T2 176 (16.9%)
T3 12 (1.1%)
T4 2 (0.2%)
Pathological N stage
NX 7 (0.7%)
N0 822 (78.7%)
N1 182 (17.4%)
N2 27 (2.6%)
N3 6 (0.6%)
aMedian value is shown with range in parentheses
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Cancer detection yield for Intramammary lesions
The abnormal interpretation rate for MR-detected intra-
mammary lesions was 7.2% (76 of 1053) and the cancer
detection rate for intramammary lesions was 3.8 per 1000
examinations (4 of 1053). The PPV1 was 5.3% (4 of 76)
and PPV3 was 15.8% (3 of 19). There was only one false-
negative result during the study period, corresponding to
the aforementioned invasive ductal carcinoma assigned as
category 3. The sensitivity of surveillance MR imaging was
75.0% (3 of 4 [95% confidence interval: 71.0%, 79.0%]) and
the specificity was 98.3% (1031 of 1049 [95% confidence
interval: 97.1%, 99.5%]).
Cancer detection yield according to interval between
initial surgery and MRI
The overall cancer detection rate for MRI was signifi-
cantly greater in MR examinations performed with more
than a 36-month interval following initial surgery than
those performed at or less than a 36-month interval
(17.4 per 1000 examinations vs. 1.4 per 1000 examina-
tions, p = 0.006). None of the other performance statis-
tics showed a significant difference between the two
groups (Table 2).
The mean interval between prior US and MR exami-
nations was slightly greater in MR examinations per-
formed ≤36 months than those performed > 36 months
following initial surgery (6.3 ± 1.0 months vs. 5.9 months
±1.6 months, p < 0.001), but with a mean difference of
0.4 months.
Discussion
With recognition of the increased future breast cancer
risk in patients with a personal history of treated breast
cancer and the decreased sensitivity of mammography in
dense breasts, several studies have recently investigated
the performance of surveillance breast MRI examina-
tions [15, 19–23]. Although the patient population and
study design differ somewhat between studies, the re-
ported cancer detection rates range from 10.0 to 18.1 per
1000 examinations [15, 19, 20, 22, 23], which are higher
than the overall cancer detection rate in our study. One
possible explanation is that 37.9% of our study population
underwent mastectomy, whereas the majority of patients
underwent breast conservation surgery in most studies
[11, 15, 22]. Another possible explanation is that the ma-
jority (88.1%) of our study population had previously
Table 2 Performance of surveillance breast MR imaging
Performance Statistics Total
(n = 1053)
Initial surgery-MR
interval≤ 36 months
(n = 709)
Initial surgery-MR
interval > 36 months
(n = 344)
p value
Cancer detection rate for MRIa 6.7 (7/1053) 1.4 (1/709) 17.4 (6/344) 0.006
Abnormal interpretation rate for MRI 84/1053 (8.0%)c 51/709 (7.2%) 33/344 (9.6%) 0.184
Cancer detection rate for
intramammary lesionsb
3.8 (4/1053) 1.41 (1/709) 8.7 (3/344) 0.105
Abnormal interpretation rate
for intramammary lesions
76/1053 (7.2%) 49/709 (6.9%) 27/344 (7.8%) 0.612
PPV1 4/76 (5.3%) 1/49 (2.0%) 3/27 (11.1%) 0.125
PPV3 3/19 (15.8%) 1/10 (10.0%) 2/9 (22.2%) 0.582
Sensitivity 3/4 (75.0%) 1/1 (100%) 2/3 (66.7%) > 0.999
Specificity 1031/1049 (98.3%) 698/708 (98.6%) 333/341 (97.6%) 0.199
aCancer detection rate for MRI is total number of intramammary and extramammary cancers detected at MR imaging per 1000 examinations
bCancer detection rate for intramammary lesions is total number of total number of intramammary cancers detected at MR imaging per 1000 examinations
cPercentage is shown in parentheses
Table 3 Clinical and Imaging Characteristics of the Four Intramammary Breast Cancers Detected on Surveillance Breast MRI
Age range,
years
Initial surgery
intervala
Prior
MRI
Side of
Lesion
MRI
assessment
Biopsy
Method
Pathology MRI
finding
Mammographic
density
Mammography
assessment
35–40 60.0 Yes Contralateral BI-RADS 3 US IDC Mass Heterogeneously
dense
BI-RADS 1
50–55 56.3 Yes Contralateral BI-RADS 4 US DCIS Nonmass Heterogeneously
dense
BI-RADS 2
45–50 24.7 Yes Contralateral BI-RADS 4 US Mucinous
carcinoma
Nonmass Heterogeneously
dense
BI-RADS 2
35–40 38.7 Yes Contralateral BI-RADS 4 MRI ILC Nonmass Heterogeneously
dense
BI-RADS 2
IDC invasive ductal carcinoma, DCIS ductal carcinoma in situ, ILC invasive lobular carcinoma
aInterval between initial surgery and screening breast MR examination by which the subsequent cancer was detected (months)
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undergone preoperative breast MR imaging, whereas only
38.9% and 54.2% of the study population in the study of
Brennan et al. and Lehman et al. had baseline preoperative
MR examinations, respectively [19, 22]. In addition, our
study population had received routine supplemental sur-
veillance US, with a median interval of 6.1 months be-
tween prior surveillance US and MR imaging. All of the
four MR-detected intramammary cancers in our study
were not detected by previous surveillance US performed
prior to MR imaging. Therefore, the MR-detected cancers
in our study are more likely to represent truly newly de-
veloped cancers after treatment of initial breast cancer,
which may be difficult to detect with surveillance US.
The fact that the cancer detection rate for MR imaging
performed at more than 3 years after surgery (17.4 per
1000) was greater than that for examinations performed
within 3 years (1.41 per 1000) may provide a basis for
establishing guidelines regarding timing of surveillance
MR imaging initiation following definitive breast cancer
surgery. Our overall cancer detection rate was similar to
the incidence cancer detection rate of screening breast
MR imaging in average risk women in a recent study
(7.5 per 1000 examinations, 13 of 1741) [24]. In another
study on women with a history of breast conservation
therapy, of whom 91.8% underwent preoperative MR im-
aging and all had undergone supplemental surveillance
US, a more than 24-month interval between initial surgery
and MR imaging was an independent factor associated
with MR-detected cancers [15]. Similar results have been
reported for breast MR imaging screening of women with
average risk of breast cancer, with no screening-detected
breast cancer diagnoses made until almost 3 years after a
negative MR study [24]. This has important implications
for the effective implementation of breast MR imaging as
a surveillance modality in the future, as breast MR im-
aging early in the post-treatment surveillance period may
have relatively low cancer yields − especially with the in-
creased use of preoperative breast MR imaging.
The overall abnormal interpretation rate (8.0%) in our
study was slightly lower than prior studies, which ranged
from 10.7% to 19.3% [15, 20, 22, 25]. Although the PPV1
(5.3%) was slightly lower than that in previous MR im-
aging studies (approximately 9.4%) [15, 20], it was still
higher than mammographic screening benchmarks from
2004 to 2008 according to the Breast Cancer Surveil-
lance Consortium (4.3%) [26]. In addition, the PPV3 in
our study for intramammary lesions, 15.8% (3 of 19), was
higher than the lower range of reported PPV values of sur-
veillance US in women with a personal history of breast
cancer, which ranged from 9.4% to 52.6% [27–30]. Re-
ported PPV values of surveillance breast MR imaging
in women with a personal history of breast cancer
have been consistently similar to or higher than that
of surveillance US [27–30]. Furthermore, surveillance
MR imaging detected three extramammary rcancers
(0.3%, 3 of 1053), which accounted for 42.8% of MR-
detected cancers. Therefore, breast MR imaging may
be more advantageous compared to US as an adjunct-
ive surveillance tool, considering its low abnormal in-
terpretation rate and ability to detect extramammary
malignancy.
Our study had several limitations. First, this was a retro-
spective study from a single institution. Although our in-
stitution recently implemented breast MRI imaging into
our post-treatment surveillance protocol to be performed
two and five years after surgery, MR imaging was also per-
formed at the request of clinicians or patients and there-
fore, the intervals between surgery and MR imaging were
variable. Second, patients underwent surveillance with
mammography and US prior to MR imaging, which could
have affected the true cancer yield of MRI. Third, the me-
dian interval between initial breast cancer surgery and
first-time surveillance MR examination (30.1 months,
range, 12.1–240.2 months) was relatively short.
Conclusions
Our data suggest that surveillance breast MR imaging
may be considered in women with a history of breast can-
cer, considering the low abnormal interpretation rate and
its high diagnostic performance. However, the cancer de-
tection rate was low and implementation may be more ef-
fective after more than 3 years after surgery. Further
research on the appropriate timing for surveillance breast
MR imaging initiation is required, especially in patients
who have undergone preoperative breast MR imaging and
supplemental surveillance US.
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